{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:12:47Z","timestamp":1790712767970,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.imlet.2024.106871","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T02:21:51Z","timestamp":1716603711000},"page":"106871","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Pathophysiology of cutaneous T-cell lymphomas: Perspective from a French referral centre"],"prefix":"10.1016","volume":"268","author":[{"given":"Ad\u00e8le","family":"De Masson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Lazaridou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Moins-Teisserenc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Ram-Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Giustiniani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Bagot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7053-7431","authenticated-orcid":false,"given":"Maxime","family":"Battistella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0409-2497","authenticated-orcid":false,"given":"Armand","family":"Bensussan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.imlet.2024.106871_bib0001","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102921","article-title":"Epidemiology of cutaneous T-cell lymphomas: a systematic review and meta-analysis of 16,953 patients","volume":"12","author":"Dobos","year":"2020","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.imlet.2024.106871_bib0002","article-title":"Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French cutaneous lymphoma registry","author":"Dobos","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.imlet.2024.106871_bib0003","article-title":"Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC","author":"Olsen","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.imlet.2024.106871_bib0004","doi-asserted-by":"crossref","first-page":"21\u20118","DOI":"10.1111\/bjd.21053","article-title":"Flow cytometry for the assessment of blood tumour burden in cutaneous T-cell lymphoma: towards a standardized approach","volume":"187","author":"Vermeer","year":"2022","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.imlet.2024.106871_bib0005","doi-asserted-by":"crossref","first-page":"1415\u201122","DOI":"10.1111\/bjd.18481","article-title":"Revisiting the initial diagnosis and blood staging of mycosis fungoides and S\u00e9zary syndrome with the KIR3DL2 marker","volume":"182","author":"Roelens","year":"2020","journal-title":"Br. J. Dermatol."},{"issue":"12","key":"10.1016\/j.imlet.2024.106871_bib0006","doi-asserted-by":"crossref","first-page":"1468\u201171","DOI":"10.1182\/blood-2017-03-772996","article-title":"Circulating and skin-derived S\u00e9zary cells: clonal but with phenotypic plasticity","volume":"130","author":"Roelens","year":"2017","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.imlet.2024.106871_bib0007","doi-asserted-by":"crossref","first-page":"247\u201157","DOI":"10.1038\/jid.2014.356","article-title":"CD158k is a reliable marker for diagnosis of S\u00e9zary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells","volume":"135","author":"Moins-Teisserenc","year":"2015","journal-title":"J. Invest. Dermatol."},{"issue":"9","key":"10.1016\/j.imlet.2024.106871_bib0008","doi-asserted-by":"crossref","first-page":"1192\u2011204","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.imlet.2024.106871_bib0009","doi-asserted-by":"crossref","first-page":"419\u201120","DOI":"10.1111\/bjd.17320","article-title":"Association of autoimmunity and long-term complete remission in patients with S\u00e9zary syndrome treated with mogamulizumab","volume":"180","author":"Bonnet","year":"2019","journal-title":"Br. J. Dermatol."},{"issue":"12","key":"10.1016\/j.imlet.2024.106871_bib0010","doi-asserted-by":"crossref","first-page":"1820\u201132","DOI":"10.1182\/blood.2021013341","article-title":"Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients","volume":"139","author":"de Masson","year":"2022","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.imlet.2024.106871_bib0011","doi-asserted-by":"crossref","first-page":"720\u20114","DOI":"10.1111\/bjd.12690","article-title":"Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas","volume":"170","author":"de Masson","year":"2014","journal-title":"Br. J. Dermatol."},{"issue":"8","key":"10.1016\/j.imlet.2024.106871_bib0012","doi-asserted-by":"crossref","first-page":"1160\u201170","DOI":"10.1016\/S1470-2045(19)30320-1","article-title":"IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial","volume":"20","author":"Bagot","year":"2019","journal-title":"Lancet Oncol."},{"issue":"10094","key":"10.1016\/j.imlet.2024.106871_bib0013","doi-asserted-by":"crossref","first-page":"555\u201166","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.imlet.2024.106871_bib0014","doi-asserted-by":"crossref","first-page":"1315\u20117","DOI":"10.1111\/bjd.18215","article-title":"Efficacy and safety of brentuximab vedotin plus bendamustine in advanced-stage primary cutaneous T-cell lymphomas","volume":"181","author":"Dumont","year":"2019","journal-title":"Br J Dermatol."},{"issue":"11","key":"10.1016\/j.imlet.2024.106871_bib0015","doi-asserted-by":"crossref","first-page":"2802\u20115","DOI":"10.1080\/10428194.2019.1599112","article-title":"Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC","volume":"60","author":"Garciaz","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.imlet.2024.106871_bib0016","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.18806","article-title":"Effectiveness of brentuximab vedotin before and after allogeneic stem-cell transplantation in the management of transformed mycosis fungoides","volume":"182","author":"Andr\u00e9","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.imlet.2024.106871_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)00329-X","article-title":"Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study","author":"de Masson","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.imlet.2024.106871_bib0018","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2021006512","article-title":"CCR8 is a new therapeutic target in cutaneous T-cell lymphomas","author":"Giustiniani","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.imlet.2024.106871_bib0019","article-title":"CD38 targeting in aggressive, treatment-refractory cutaneous T-cell lymphomas","author":"Van Anh","year":"2023","journal-title":"J. Invest. Dermatol."},{"issue":"10","key":"10.1016\/j.imlet.2024.106871_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2022.07.037","article-title":"Exploring the nonlymphocytic cutaneous microenvironment in advanced cutaneous T-cell lymphomas using single-cell RNA sequencing","volume":"143","author":"Calugareanu","year":"2023","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.imlet.2024.106871_bib0021","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3390\/cancers15030746","article-title":"Mycosis fungoides and S\u00e9zary syndrome: microenvironment and cancer progression","volume":"15","author":"Dobos","year":"2023","journal-title":"Cancers (Basel)."},{"issue":"6","key":"10.1016\/j.imlet.2024.106871_bib0022","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood."},{"issue":"440","key":"10.1016\/j.imlet.2024.106871_bib0023","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar5894","article-title":"High-throughput sequencing of the T cell receptor \u03b2 gene identifies aggressive early-stage mycosis fungoides","volume":"10","author":"de Masson","year":"2018","journal-title":"Sci Transl Med."},{"issue":"3","key":"10.1016\/j.imlet.2024.106871_bib0024","doi-asserted-by":"crossref","first-page":"679\u201180","DOI":"10.1111\/bjd.20432","article-title":"Diagnostic performance of high-throughput sequencing of the T-cell receptor beta gene for the diagnosis of cutaneous T-cell lymphoma","volume":"185","author":"Zimmermann","year":"2021","journal-title":"Br J Dermatol."},{"issue":"3","key":"10.1016\/j.imlet.2024.106871_bib0025","doi-asserted-by":"crossref","first-page":"364\u201174","DOI":"10.1309\/25E9Y7RRAY84HTAT","article-title":"A comparison of morphologic features, flow cytometry, TCR-Vbeta analysis, and TCR-PCR in qualitative and quantitative assessment of peripheral blood involvement by S\u00e9zary syndrome","volume":"125","author":"Morice","year":"2006","journal-title":"Am J Clin Pathol."},{"issue":"24","key":"10.1016\/j.imlet.2024.106871_bib0026","doi-asserted-by":"crossref","first-page":"2539\u201154","DOI":"10.1182\/blood.2021012286","article-title":"Improved S\u00e9zary cell detection and novel insights into immunophenotypic and molecular heterogeneity in S\u00e9zary syndrome","volume":"138","author":"Najidh","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.imlet.2024.106871_bib0027","doi-asserted-by":"crossref","first-page":"1010\u201125","DOI":"10.1111\/bjd.21018","article-title":"Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in S\u00e9zary syndrome","volume":"186","author":"Roelens","year":"2022","journal-title":"Br J Dermatol."},{"issue":"5","key":"10.1016\/j.imlet.2024.106871_bib0028","doi-asserted-by":"crossref","first-page":"1388\u201191","DOI":"10.1182\/blood.V97.5.1388","article-title":"CD4(+) cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor","volume":"97","author":"Bagot","year":"2001","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.imlet.2024.106871_bib0029","article-title":"CD158k\/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome","volume":"122","author":"Poszepczynska-Guign\u00e9","year":"2004","journal-title":"J Invest Dermatol. mars"},{"issue":"117","key":"10.1016\/j.imlet.2024.106871_bib0030","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003008","article-title":"Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients","volume":"4","author":"Clark","year":"2012","journal-title":"Sci Transl Med."},{"issue":"2","key":"10.1016\/j.imlet.2024.106871_bib0031","doi-asserted-by":"crossref","first-page":"258\u201164","DOI":"10.1111\/j.1365-2133.2004.06325.x","article-title":"Circulating clonal CLA(+) and CD4(+) T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7","volume":"152","author":"Sokolowska-Wojdylo","year":"2005","journal-title":"Br J Dermatol."},{"issue":"14","key":"10.1016\/j.imlet.2024.106871_bib0032","doi-asserted-by":"crossref","first-page":"4443\u201154","DOI":"10.1158\/1078-0432.CCR-19-0148","article-title":"Single-cell lymphocyte heterogeneity in advanced cutaneous T-cell lymphoma skin tumors","volume":"25","author":"Gaydosik","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"21","key":"10.1016\/j.imlet.2024.106871_bib0033","doi-asserted-by":"crossref","first-page":"3331\u20115","DOI":"10.4161\/15384101.2014.965061","article-title":"Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression","volume":"13","author":"Netchiporouk","year":"2014","journal-title":"Cell Cycle"},{"issue":"5","key":"10.1016\/j.imlet.2024.106871_bib0034","doi-asserted-by":"crossref","first-page":"1428\u201135","DOI":"10.1038\/jid.2013.488","article-title":"The role of IL-32 in cutaneous T-cell lymphoma","volume":"134","author":"Suga","year":"2014","journal-title":"J Invest Dermatol."},{"issue":"12","key":"10.1016\/j.imlet.2024.106871_bib0035","doi-asserted-by":"crossref","first-page":"2610\u201122","DOI":"10.1158\/1078-0432.CCR-21-4437","article-title":"Single-cell RNA sequencing unveils the clonal and transcriptional landscape of cutaneous T-cell lymphomas","volume":"28","author":"Gaydosik","year":"2022","journal-title":"Clin Cancer Res."},{"issue":"12","key":"10.1016\/j.imlet.2024.106871_bib0036","doi-asserted-by":"crossref","first-page":"1426\u201134","DOI":"10.1038\/ng.3444","article-title":"Genomic profiling of S\u00e9zary syndrome identifies alterations of key T cell signaling and differentiation genes","volume":"47","author":"Wang","year":"2015","journal-title":"Nat Genet."},{"issue":"16","key":"10.1016\/j.imlet.2024.106871_bib0037","doi-asserted-by":"crossref","first-page":"2115\u201126","DOI":"10.1182\/bloodadvances.2018022608","article-title":"Single-cell heterogeneity in S\u00e9zary syndrome","volume":"2","author":"Buus","year":"2018","journal-title":"Blood Adv."},{"issue":"11","key":"10.1016\/j.imlet.2024.106871_bib0038","doi-asserted-by":"crossref","first-page":"4331\u201141","DOI":"10.1182\/blood.V91.11.4331","article-title":"Isolation of tumor-specific cytotoxic CD4+ and CD4+CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma","volume":"91","author":"Bagot","year":"1998","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.imlet.2024.106871_bib0039","doi-asserted-by":"crossref","first-page":"20\u20118","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and s\u00e9zary syndrome: a multicenter phase II study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J Clin Oncol."},{"issue":"6","key":"10.1016\/j.imlet.2024.106871_bib0040","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.17194","article-title":"Infections in mycosis fungoides and S\u00e9zary syndrome are a frequent cause of morbidity and contribute to mortality. What can be done?","volume":"179","author":"Scarisbrick","year":"2018","journal-title":"Br. J. Dermatol."},{"issue":"12","key":"10.1016\/j.imlet.2024.106871_bib0041","doi-asserted-by":"crossref","first-page":"4059\u201166","DOI":"10.1182\/blood-2003-04-1044","article-title":"Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma","volume":"102","author":"Yawalkar","year":"2003","journal-title":"Blood."},{"issue":"14","key":"10.1016\/j.imlet.2024.106871_bib0042","doi-asserted-by":"crossref","first-page":"3755\u201163","DOI":"10.1158\/1078-0432.CCR-12-3488","article-title":"TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma","volume":"19","author":"Guenova","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.imlet.2024.106871_bib0043","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170015","article-title":"The mycosis fungoides cutaneous microenvironment shapes dysfunctional cell trafficking, antitumor immunity, matrix interactions, and angiogenesis","volume":"8","author":"Gaydosik","year":"2023","journal-title":"JCI. Insight."},{"issue":"6","key":"10.1016\/j.imlet.2024.106871_bib0044","doi-asserted-by":"crossref","first-page":"1405\u201110","DOI":"10.1046\/j.1523-1747.2002.19610.x","article-title":"Increased CCR4 expression in cutaneous T cell lymphoma","volume":"119","author":"Ferenczi","year":"2002","journal-title":"J. Invest. Dermatol."},{"issue":"44","key":"10.1016\/j.imlet.2024.106871_bib0045","doi-asserted-by":"crossref","first-page":"17945\u201150","DOI":"10.1073\/pnas.1316796110","article-title":"Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans","volume":"110","author":"Sugiyama","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"issue":"2","key":"10.1016\/j.imlet.2024.106871_bib0046","first-page":"213\u20116","article-title":"Mogamulizumab-induced vitiligo in patients with S\u00e9zary syndrome: three cases","volume":"31","author":"Algarni","year":"2021","journal-title":"Eur J Dermatol."},{"issue":"10","key":"10.1016\/j.imlet.2024.106871_bib0047","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3527","article-title":"Mogamulizumab-induced mucocutaneous lichenoid reaction: a case report and short review","volume":"100","author":"Trager","year":"2020","journal-title":"Acta Derm. Venereol."},{"issue":"156 Suppl 1","key":"10.1016\/j.imlet.2024.106871_bib0048","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S0959-8049(21)00716-4","article-title":"Granulomatous rash associated with mogamulizumab mimicking mycosis fungoides: a case series","author":"Wang","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.imlet.2024.106871_bib0049","doi-asserted-by":"crossref","first-page":"1639\u201150","DOI":"10.4049\/jimmunol.1701377","article-title":"CCR8 expression defines tissue-resident memory T cells in human skin","volume":"200","author":"McCully","year":"2018","journal-title":"J. Immunol."},{"issue":"279","key":"10.1016\/j.imlet.2024.106871_bib0050","doi-asserted-by":"crossref","first-page":"279ra39","DOI":"10.1126\/scitranslmed.3010302","article-title":"Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells","volume":"7","author":"Watanabe","year":"2015","journal-title":"Sci Transl Med."},{"issue":"11","key":"10.1016\/j.imlet.2024.106871_bib0051","doi-asserted-by":"crossref","first-page":"2983\u201194","DOI":"10.1158\/0008-5472.CAN-20-3585","article-title":"Fc-optimized anti-CCR8 antibody depletes regulatory T cells in human tumor models","volume":"81","author":"Campbell","year":"2021","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.imlet.2024.106871_bib0052","doi-asserted-by":"crossref","first-page":"1122\u20116","DOI":"10.1016\/j.jid.2023.02.011","article-title":"CD38 targeting holds potential for the treatment of aggressive refractory cutaneous T-cell lymphomas","volume":"143","author":"Pavlova","year":"2023","journal-title":"J. Invest. Dermatol."},{"issue":"13","key":"10.1016\/j.imlet.2024.106871_bib0053","doi-asserted-by":"crossref","first-page":"1072\u201183","DOI":"10.1182\/blood.2018888107","article-title":"Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma","volume":"134","author":"Lindahl","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.imlet.2024.106871_bib0054","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41408-020-0324-3","article-title":"Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in S\u00e9zary syndrome","volume":"10","author":"Willerslev-Olsen","year":"2020","journal-title":"Blood Cancer J."},{"issue":"10","key":"10.1016\/j.imlet.2024.106871_bib0055","doi-asserted-by":"crossref","first-page":"2449\u201158","DOI":"10.1016\/j.jid.2021.01.038","article-title":"Staphylococcus aureus induces signal transducer and activator of transcription 5\u2012dependent miR-155 expression in cutaneous T-cell lymphoma","volume":"141","author":"Willerslev-Olsen","year":"2021","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.imlet.2024.106871_bib0056","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2023021671","article-title":"Staphylococcus aureus induce drug resistance in cancer T cells in S\u00e9zary Syndrome","author":"Vadivel","year":"2024","journal-title":"Blood"}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247824000452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247824000452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T16:58:41Z","timestamp":1720544321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247824000452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":56,"alternative-id":["S0165247824000452"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2024.106871","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathophysiology of cutaneous T-cell lymphomas: Perspective from a French referral centre","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2024.106871","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Federation of Immunological Societies. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106871"}}